Isis
AZ licenses kidney drug from Ionis for $330m
February 21, 2018Research and Development, Sales and Marketing AstraZeneca, Ionis, Isis, biotech, drugs, kidney, pharma, pharmaceutical
AstraZeneca continues to build on its relationship with San Diego-based Ionis Pharmaceuticals, this time by agreeing a licensing deal for …
Bayer buys blood-thinning drug from Isis
May 5, 2015Research and Development, Sales and Marketing Bayer, Eliquis, ISIS-FXI, Isis, Xarelto, blooding thinning
German drug giant Bayer is sealing a $155 million deal with Isis Pharmaceuticals to gain access to its anti-clotting treatment …
J&J acquires Index Ventures-owned firm XO1
March 23, 2015Sales and Marketing Index Ventures, Isis, J&J, JJ, Janssen, vectura, xo1
Johnson & Johnson’s pharma unit Janssen has acquired Index Ventures’ biopharma firm XO1 Limited that develops the promising anti-thrombin antibody …
Isis and J&J sign RNA deal
January 8, 2015Research and Development, Sales and Marketing Isis, J&J, JJ, Janssen, RNA, gastrointestinal tract
Isis Pharmaceuticals is collaborating with Johnson & Johnson’s pharma unit Janssen to develop antisense drugs to treat autoimmune disorders. The …
Biogen signs neurology deal
September 11, 2013Research and Development, Sales and Marketing Biogen IDEC, Isis, antisense, neurology
Biogen Idec and Isis Pharmaceuticals have entered their fourth partnership in two years in a deal that will see the …
Roche signs Huntington’s deal
April 10, 2013Research and Development, Sales and Marketing Huntington's, Isis, Roche
Roche is to pay California-based Isis Pharmaceuticals $30 million upfront to cement a new alliance in which the firms will …
Pharma manufacturing news in brief
August 14, 2012Manufacturing and Production Advanced Bioscience, Almac, Amneal, Cipla, Isis, Sanofi Pasteur
Cipla opening three new API plants as Indian trade delegations forges closer ties with Sri Lanka; plus facility updates from …
GSK signs RNA therapeutics alliance
March 31, 2010Research and Development GlaxoSmithKline, Isis, RNA
GlaxoSmithKline has forged a new strategic alliance with Isis Pharmaceuticals to exploit the specialist company’s expertise in anti-RNA therapeutics. California-based …
Latest content
Five Facts about cardiovascular disease
